GENZYME-GE(NSDQ:GENZ)
|
Genzyme Corporation is a global biotechnology company dedicated to making a major positive impact on the lives of people with serious diseases. The company''s broad product portfolio is focused on rare genetic disorders, renal disease, and osteoarthritis, and includes an industry-leading array of diagnostic products and services. Genzyme''s commitment to innovation continues today with research into novel approaches to cancer, heart disease, and other areas of unmet medical need.
|
# Employees: 10000
|
|
Address: 500 Kendall Street,Cambridge,MA,USA
|
|
Phone: 617 252-7500
|
Fax: 617-494-6561
|
|
Website: www.genzyme.com
|
Email: information@genzyme.com
|
Sector: Medical
|
Industry: MED-BIOMED/GENE
|
Executive Officers
Dividend
Ex-Dividend Date: N/A
Annual Dividend: N/A
Current Dividend Yield: N/A
Dividend Paid (3 months): N/A
Indicated Dividend: N/A
Earnings
|
Last Earnings Date: 6/30/2008
|
|
Next Earnings Date(Expected): 10/22/2008
|
|
Mean EPS (Next Qtr): $0.86
|
|
Mean EPS (Year): $3.43
|
|
Mean Estimate(Long Term): $16.45
|
|
P/E Ratio(Based on EPS estimate): 22.660
|
|
Number of Estimates: 8
|
|
Shares Performance
|
Period
|
GENZ
|
Compare to S&P
|
| YTD |
4.57 %
|
20.40 %
|
| 4 Weeks |
-0.31 %
|
0.26 %
|
| 12 Weeks |
16.25 %
|
23.61 %
|
Shares Information
|
Analyst Coverage: Y
|
Avg Volume: 2420668
|
|
Shares Outstanding: 268M
|
Market Cap: $20.91B
|
| 52 Week High: $83.25
|
52 Week Low: $61.96
|
| P/E Ratio: 23.240
|
PEG Ratio: 1.380
|
|
Split: On 6/4/2001 GENZ split by factor of 2.000
|
Earnings Performance
EPS Growth in Last Quarter: -3.57 %
EPS Growth in Last Year: 19.12 %
Sales Growth in Last Quarter: 6.46 %
Sales Growth in Last Quarter: 25.47 %
Financials
|
Qtr Book Value: $2.95
|
|
Cash Flow/Share: $18.07
|
|
Change in Payout Ratio: 0.000
|
|
Price/Sales: 4.900
|
|
